

CONTINUING REVIEW APPROVAL

February 9, 2021

Stephanie Page
slpage@cmh.edu

Dear Dr. Page:

On 2/7/2021, the CM IRB reviewed the following submission:

Type of Review:	Continuing Review
Title:	The Role of Exhaled Nitric Oxide (FeNO) in Eosinophilic Esophagitis: Pilot Study to Evaluate the Correlation of FeNO and Esophageal Eosinophils
Investigator:	Stephanie Page
myIRB ID:	CR00002282 for ID# 11120665
Funding:	Allergan, Grant Office ID: N/A
IND, IDE, or HDE:	None
Documents Reviewed:	None

The CM IRB reviewed and approved the above-titled submission under expedited review (45 CFR 46.110) from **2/7/2021 to 2/6/2022** inclusive.

Before 2/6/2022 or within 30 days of study close, whichever is earlier, you are to submit a completed continuing review and required attachments to request continuing approval or closure. You can submit a continuing review by navigating to the active study and clicking Create Modification / CR.

If continuing review approval is not granted before the expiration date of 2/6/2022, approval of this study expires on that date.

The IRB approved the submission as Child Risk Category 1 under 45 CFR 46.404 and under expedited categories 3, 4, and 7(b) (45 CFR 46.110) with one parental/LAR signature required on the permission/assent form.

In conducting this protocol, you are required to follow the requirements listed in the [Human Research Protection Program Investigator Manual \(HRP-103\)](#).

Sincerely,
Dane Sommer, DMin
Co-Chair, CM Institutional Review Board



Doug Swanson, MD

Co-Chair, CM Institutional Review Board

Ryan McDowell

Director, Office of Research Integrity